Cannabis Lucy Scientific Discovery acquires High Times IP, expects $10M of revenue growth in 2024 Lucy also expects to add $5 million of EBITDA to its financial results next year from the deal Rowan DunneSeptember 8, 2023
Cannabis Final arguments presented in Tobagrown’s legal battle against Manitoba’s cannabis cultivation ban The non-profit is organizing a rally at the Manitoba Legislative Building on Friday Natalia Buendia CalvilloSeptember 7, 2023
AI and Autonomy HumanFirst connects clinical researchers to vital data using artificial intelligence-based platform HumanFirst's platform offers cost reduction and risk mitigation for trial portfolios Joseph MortonSeptember 7, 2023
Cannabis Avextra starts exporting cannabis-based products to Switzerland and Austria Avextra’s cannabis-based medicines are now present in six European markets Natalia Buendia CalvilloSeptember 7, 2023
Gold Heliostar Metals’ Ana Paula project strikes gold with drill results pointing to major resource expansion Heliostar is set to deliver on its three-pronged approach to the re-scoping of Ana Paula in 2023 Natalia Buendia CalvilloSeptember 7, 2023
Gold i-80 Gold intercepts 10.6 g/t over 38.8 metres at McCoy-Cove, Nevada The company reported a series of high-grade drill results from 5 holes at the property on Thursday Rowan DunneSeptember 7, 2023
Gold Skeena Resources updates mineral resource estimate at Snip Gold Project in British Columbia The combined efforts of these programs resulted in the identification of new zones of mineralization Joseph MortonSeptember 7, 2023
Uranium Centrus Energy to begin producing high-assay low-enriched uranium at Ohio plant 'This will be the first new U.S.-owned uranium enrichment plant to begin production since 1954,' says the company's CEO Rowan DunneSeptember 7, 2023
Mining Defense Metals airborne survey finds new anomalies at Wicheeda rare earth project The company discovered two previously unknown readings indicating the presence of REE as part of the study Joseph MortonSeptember 6, 2023
News Clearmind to collaborate with Johns Hopkins University to study promising psychedelic treatment for alcohol use disorder Johns Hopkins University School of Medicine is the second U.S. clinical site to join Clearmind's trial, following Yale School of Medicine's psychiatry department Natalia Buendia CalvilloSeptember 6, 2023